Seres Health Closes $48 Million Series C Financing

Seres Health Closes $48 Million Series C Financing

December 2, 2014

CAMBRIDGE, Mass., Dec. 2, 2014 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, announced today that it has closed its Series C round with $48 million in new investment.

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for a Broad Range of Therapeutic and Agricultural Applications

Editas Medicine Licenses Genome Editing Technology from Duke University

Editas Medicine Licenses Genome Editing Technology from Duke University

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for the Development of Human Therapeutics  

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

December 1, 2014

STRATEGIC AGREEMENT ALLOWS FOR ADDITIONAL THERAPEUTIC LICENSING ON A GENE-BY-GENE BASIS

BOSTON and CAMBRIDGE, Mass., Dec. 1, 2014 /PRNewswire-USNewswire/ -- The Broad Institute, Harvard University, the Massachusetts Institute of Technology and Editas Medicine have entered into a worldwide license agreement to grant Editas access to intellectual property related to certain genome editing technology for the development of human therapeutic applications.

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Eleven Biotherapeutics Announces Additional Financing of $20 Million

November 25, 2014

 Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

November 19, 2014

 - Phase 2 study met primary objective of showing anti-tumor activity as measured by overall response rate at Q3W dosing schedule -

- Promising anti-tumor activity and survival in patients with KRAS mutant tumors and squamous histology -

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

November 18, 2014

 -Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -

-Data Support Initiation of Multiple Expansion Cohorts in the First Half of 2015-

Black Duck Software Appoints Global Sales Veteran Adam Clay as Vice President of Worldwide Sales

Black Duck Software Appoints Global Sales Veteran Adam Clay as Vice President of Worldwide Sales

November 18, 2014

Black Duck Software, the leading OSS Logistics solutions provider enabling the deployment and management of open source software (OSS), today announced the appointment of Adam Clay as Vice President of Worldwide Sales.

Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer

Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer

November 17, 2014

CAMBRIDGE, Mass., Nov. 17, 2014 /PRNewswire/ -- Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.

Joule Names Industry Veteran Serge Tchuruk as President and CEO

Joule Names Industry Veteran Serge Tchuruk as President and CEO

November 13, 2014

Tchuruk will lead the organization in its transition towards commercialization